Concept Life Sciences offers a consultative approach and a suite of customisable assays for investigating CNS (central nervous system) test compounds, including specialist histology readouts as well as ADME services and ensuring a comprehensive, tailored CNS program. We gather robust data to drive confident decision making throughout your CNS drug discovery and development pipeline.
We have world-leading experts in the research of multiple sclerosis (MS), a disease that requires understanding of immunology, inflammation and neuroscience. We can provide end-to-end support for MS drug discovery through in vitro OPC (Oligodendrocyte Precursor Cells) assays and our ex vivo slice model, a powerful screening and translational tool as well as lead compound assessment in our in vivo EAE, cuprizone and LPS MS models.
At Concept, our experienced Neuroscience team offer specialist discovery services to clients looking to develop novel therapies for a range of neurodegenerative conditions. We can tailor and develop neuroprotective screening assays to discover the mechanism of action of your drug candidate, with customised assays targeting neurons themselves and/or the supportive glial cells in isolation or co-culture.
We are developing a range of neurotoxicity services, including developmental neurotoxicity assays (DNT), using our pluripotent stem cell and primary CNS cell-based assay platforms that can support Pharma and non-Pharma clients in their regulatory and safety requirements.